Literature DB >> 20714884

Prognostic factors for patients after curative resection for proximal gastric cancer.

Donghui Zhao1, Huimian Xu, Kai Li, Zhe Sun.   

Abstract

The factors influencing the long-term survival of patients with proximal gastric cancer (PGC) after curative resection were investigated. Data from 171 patients who underwent curative resection for PGC were retrospectively analyzed. The patients were grouped according to the clinicopathological factors and operative procedures. The tumor depth (T stage) and lymph node metastasis (pN stage) were graded according to the fifth edition of TNM Staging System published by UICC in 1997. The metastatic lymph node ratio (MLR) was divided into four levels: 0%, <10%, 10%-30% and >30%. The data of survival rate were analyzed by Kaplan-Meier method (log-rank test) and Cox regression model. The 5-year overall survival rate of 171 patients was 37.32%. The univariate analysis demonstrated that the survival time of the postoperative patients with PGC was related to tumor size (chi2=4.57, P=0.0325), gross type (chi2=21.38, P<0.001), T stage (chi2=27.91, P<0.001), pN stage (chi2=44.72, P<0.001), MLR (chi2=61.12, P<0.001), TNM stage (chi2=44.91, P<0.001), and range of gastrectomy (chi2=4.36, P=0.0368). Multivariate analysis showed that MLR (chi2=10.972, P=0.001), pN stage (chi2=6.640, P=0.010), TNM stage (chi2=7.081, P=0.007), T stage (chi2=7.687, P=0.006) and gross type (chi2=6.252, P=0.012) were the independent prognostic factors. In addition, the prognosis of patients who underwent total gastrectomy (TG) was superior to that of patients who underwent proximal gastrectomy (PG) for the cases of tumor>or=5 cm (chi2=6.31, P=0.0120), Borrmann III/IV (chi2=7.96, P=0.0050), T4 (chi2=4.57, P=0.0325), pN2 (chi2=5.52, P=0.0188), MLR 10%-30% (chi2=4.46, P=0.0347), MLR>30% (chi2=13.34, P=0.0003), TNM III (chi2=14.05, P=0.0002) or TNM IV stage (chi2=4.37, P=0.0366); and combining splenectomy was beneficial to the cases of T3 (chi2=5.68, P=0.0171) or MLR>30% (chi2=6.11, P=0.0134). It was concluded that MLR, pN stage, TNM stage, T stage, and gross type had advantages in providing a precise prognostic evaluation for patients undergoing curative resection for PGC, in which MLR was the most valuable index. TG and combining splenectomy were useful to improve the prognosis to patients with PGC of TNM III/IV stage, serosa invasion, or extensive regional lymph node metastasis.

Entities:  

Mesh:

Year:  2010        PMID: 20714884     DOI: 10.1007/s11596-010-0463-z

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  33 in total

1.  Effect of simultaneous splenectomy on the survival of patients undergoing curative gastrectomy for proximal gastric carcinoma.

Authors:  Suphan Erturk; Yilmaz Ersan; Yusuf Cicek; Gulen Dogusoy; Mustafa Senocak
Journal:  Surg Today       Date:  2003       Impact factor: 2.549

2.  Total gastrectomy for gastric carcinoma.

Authors:  Ali Serdar Isgüder; Okay Nazli; Tugrul Tansug; Ali Dogan Bozdag; Mehmet Ali Onal
Journal:  Hepatogastroenterology       Date:  2005 Jan-Feb

3.  Comparison of results of surgery in the upper third and more distal stomach.

Authors:  Chikara Kunisaki; Hiroshi Shimada; Hidetaka Andrew Ono; Yuichi Otsuka; Goro Matsuda; Masato Nomura; Hirotoshi Akiyama
Journal:  J Gastrointest Surg       Date:  2006-05       Impact factor: 3.452

4.  Proximal versus distal gastric carcinoma--what are the differences?

Authors:  P Piso; U Werner; H Lang; P Mirena; J Klempnauer
Journal:  Ann Surg Oncol       Date:  2000-08       Impact factor: 5.344

5.  A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma.

Authors:  Attila Csendes; Patricio Burdiles; Jorge Rojas; Italo Braghetto; Juan Carlos Diaz; Fernando Maluenda
Journal:  Surgery       Date:  2002-04       Impact factor: 3.982

6.  Procedure for lymph node dissection around splenic artery in proximal gastric cancer.

Authors:  Masakazu Ohno; Takeshi Nakamura; Tetsuo Ajiki; Hideki Horiuchi; Yoshiki Tabuchi; Yoshikazu Kuroda
Journal:  Hepatogastroenterology       Date:  2003 Jul-Aug

7.  Clinical outcome of proximal versus total gastrectomy for proximal gastric cancer.

Authors:  Norio Shiraishi; Yosuke Adachi; Seigo Kitano; Kenji Kakisako; Masafumi Inomata; Kazuhiro Yasuda
Journal:  World J Surg       Date:  2002-06-25       Impact factor: 3.352

8.  Association of splenectomy with postoperative complications in patients with proximal gastric and gastroesophageal junction cancer.

Authors:  Jürgen Weitz; David P Jaques; Murray Brennan; Martin Karpeh
Journal:  Ann Surg Oncol       Date:  2004-07       Impact factor: 5.344

9.  Time trends in gastric carcinoma: changing patterns of type and location.

Authors:  M E Craanen; W Dekker; P Blok; J Ferwerda; G N Tytgat
Journal:  Am J Gastroenterol       Date:  1992-05       Impact factor: 10.864

10.  Distribution of lymph node metastasis including micrometastasis in gastric cancer with submucosal invasion.

Authors:  Hiroshi Higashi; Shoji Natsugoe; Sumiya Ishigami; Yoshikazu Uenosono; Masataka Matsumoto; Akihiro Nakajo; Futoshi Miyazono; Shuichi Hokita; Sonshin Takao; Takashi Aikou
Journal:  World J Surg       Date:  2003-04       Impact factor: 3.352

View more
  3 in total

1.  Prognostic and clinical significance of STAT3 and MMP9 in patients with gastric cancer: a meta-analysis of a Chinese cohort.

Authors:  Jing Chen; Xiaoxia Liu; Haiyan Jiao; Liang Peng; Zhenghao Huo; Wenjun Yang; Qin Shen; Tao Li; Qilun Liu
Journal:  Int J Clin Exp Med       Date:  2015-01-15

Review 2.  The prognostic role of matrix metalloproteinase 2 in gastric cancer: a systematic review with meta-analysis.

Authors:  Weisong Shen; Hongqing Xi; Bo Wei; Lin Chen
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-08       Impact factor: 4.553

3.  Clinical outcomes of proximal gastrectomy versus total gastrectomy for locally advanced proximal gastric cancer: a propensity score matching analysis.

Authors:  Lulu Zhao; Rui Ling; Fuhai Ma; Hu Ren; Hong Zhou; Tongbo Wang; Yingtai Chen; Shangying Hu; Dongbing Zhao
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.